BRIEF-Kintara Therapeutics, Tuhura Biosciences Enter Into Merger Agreement

Reuters04-03

April 3 (Reuters) - Kintara Therapeutics Inc :

* KINTARA THERAPEUTICS AND TUHURA BIOSCIENCES ENTER INTO DEFINITIVE MERGER AGREEMENT

* KINTARA THERAPEUTICS INC - $31 MILLION SUBSCRIBED FINANCING BY TUHURA IN CONNECTION WITH MERGER AGREEMENT EXPECTED TO PROVIDE CASH RUNWAY INTO LATE 2025

* KINTARA THERAPEUTICS INC - COMBINED COMPANY IS EXPECTED TO OPERATE UNDER NAME "TUHURA BIOSCIENCES, INC."

* KINTARA THERAPEUTICS - ON A PRO FORMA BASIS, POST-MERGER CO'S EQUITYHOLDERS EXPECTED TO COLLECTIVELY OWN UP TO ABOUT 2.85%, OR APPROXIMATELY 5.45%

* KINTARA THERAPEUTICS INC - TUHURA EQUITYHOLDERS ARE EXPECTED TO COLLECTIVELY OWN APPROXIMATELY 97.15%, OR 94.55% ASSUMING DISTRIBUTION OF CVR SHARES

* KINTARA THERAPEUTICS INC -COMBINED COMPANY IS EXPECTED TO TRADE ON NASDAQ CAPITAL MARKET ("NASDAQ") UNDER TICKER "HURA"

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2424815433?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-04-03 19:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2424815433","market":"us","top_or_hot":-1,"title":"BRIEF-Kintara Therapeutics, Tuhura Biosciences Enter Into Merger Agreement","media":"Reuters","content":"<html><body><p>April 3 (Reuters) - Kintara <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc   :</p><p>   * KINTARA THERAPEUTICS AND TUHURA BIOSCIENCES ENTER INTO DEFINITIVE MERGER AGREEMENT</p><p>   * KINTARA THERAPEUTICS INC - $31 MILLION SUBSCRIBED FINANCING BY TUHURA IN CONNECTION WITH MERGER AGREEMENT EXPECTED TO PROVIDE CASH RUNWAY INTO LATE 2025</p><p>   * KINTARA THERAPEUTICS INC - COMBINED COMPANY IS EXPECTED TO OPERATE UNDER NAME \"TUHURA BIOSCIENCES, INC.\"</p><p>   * KINTARA THERAPEUTICS - ON A PRO FORMA BASIS, POST-MERGER CO'S EQUITYHOLDERS EXPECTED TO COLLECTIVELY OWN UP TO ABOUT 2.85%, OR APPROXIMATELY 5.45%</p><p>   * KINTARA THERAPEUTICS INC - TUHURA EQUITYHOLDERS ARE EXPECTED TO COLLECTIVELY OWN APPROXIMATELY 97.15%, OR 94.55% ASSUMING DISTRIBUTION OF CVR SHARES</p><p>   * KINTARA THERAPEUTICS INC -COMBINED COMPANY IS EXPECTED TO TRADE ON NASDAQ CAPITAL MARKET (\"NASDAQ\") UNDER TICKER \"HURA\"</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Kintara Therapeutics, Tuhura Biosciences Enter Into Merger Agreement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Kintara Therapeutics, Tuhura Biosciences Enter Into Merger Agreement\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-03 19:14 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>April 3 (Reuters) - Kintara Therapeutics Inc   :   * KINTARA THERAPEUTICS AND TUHURA BIOSCIENCES ENTER INTO DEFINITIVE MERGER AGREEMENT   * KINTARA THERAPEUTICS INC - $31 MILLION SUBSCRIBED FINANCING ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"QID","symbol_name":"纳指两倍做空ETF","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2424815433","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2424815433","pubTimestamp":1712142875,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"April 3  - Kintara Therapeutics Inc   :   * KINTARA THERAPEUTICS AND TUHURA BIOSCIENCES ENTER INTO DEFINITIVE MERGER AGREEMENT   * KINTARA THERAPEUTICS INC - $31 MILLION SUBSCRIBED FINANCING BY TUHURA IN CONNECTION WITH MERGER AGREEMENT EXPECTED TO PROVIDE CASH RUNWAY INTO LATE 2025   * KINTARA THERAPEUTICS INC - COMBINED COMPANY IS EXPECTED TO OPERATE UNDER NAME \"TUHURA BIOSCIENCES, INC.\"   * KINTARA THERAPEUTICS - ON A PRO FORMA BASIS, POST-MERGER CO'S EQUITYHOLDERS EXPECTED TO COLLECTIVELY OWN UP TO ABOUT 2.85%, OR APPROXIMATELY 5.45%   * KINTARA THERAPEUTICS INC - TUHURA EQUITYHOLDERS ARE EXPECTED TO COLLECTIVELY OWN APPROXIMATELY 97.15%, OR 94.55% ASSUMING DISTRIBUTION OF CVR SHARES   * KINTARA THERAPEUTICS INC -COMBINED COMPANY IS EXPECTED TO TRADE ON NASDAQ CAPITAL MARKET  UNDER TICKER \"HURA\"Source text for Eikon:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"QID":"纳指两倍做空ETF","KTRA":"Kintara Therapeutics, Inc.","BK4139":"生物科技","PSQ":"纳指反向ETF","QLD":"纳指两倍做多ETF","QQQ":"纳指100ETF","SQQQ":"纳指三倍做空ETF","LENZ":"Therapeutics",".IXIC":"NASDAQ Composite","TQQQ":"纳指三倍做多ETF"},"translate_title":"简介——金塔拉治疗公司与图胡拉生物科学公司达成合并协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"KTRA":0.9,".IXIC":0.78,"MNQmain":0.6,"NQmain":0.6,"PSQ":0.6,"QID":0.6,"QLD":0.6,"QQQ":0.6,"SQQQ":0.6,"TQQQ":0.6},"content_text":"April 3 (Reuters) - Kintara Therapeutics Inc   :   * KINTARA THERAPEUTICS AND TUHURA BIOSCIENCES ENTER INTO DEFINITIVE MERGER AGREEMENT   * KINTARA THERAPEUTICS INC - $31 MILLION SUBSCRIBED FINANCING BY TUHURA IN CONNECTION WITH MERGER AGREEMENT EXPECTED TO PROVIDE CASH RUNWAY INTO LATE 2025   * KINTARA THERAPEUTICS INC - COMBINED COMPANY IS EXPECTED TO OPERATE UNDER NAME \"TUHURA BIOSCIENCES, INC.\"   * KINTARA THERAPEUTICS - ON A PRO FORMA BASIS, POST-MERGER CO'S EQUITYHOLDERS EXPECTED TO COLLECTIVELY OWN UP TO ABOUT 2.85%, OR APPROXIMATELY 5.45%   * KINTARA THERAPEUTICS INC - TUHURA EQUITYHOLDERS ARE EXPECTED TO COLLECTIVELY OWN APPROXIMATELY 97.15%, OR 94.55% ASSUMING DISTRIBUTION OF CVR SHARES   * KINTARA THERAPEUTICS INC -COMBINED COMPANY IS EXPECTED TO TRADE ON NASDAQ CAPITAL MARKET (\"NASDAQ\") UNDER TICKER \"HURA\"Source text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2424815433"}